Abstracts tagged "Joint Structure"

Abstract Number: 0748 • ACR Convergence 2020
Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis
Andreas Kerschbaumer¹, Gabriela Supp², Farideh Alasti¹, Josef Smolen² and Daniel Aletaha¹, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized through symmetric polyarthritis leading to joint destruction over time in many patients. Radiographic damage is…
Abstract Number: 1113 • ACR Convergence 2020
Intrameniscal Signal Alterations Strongly Predict Destabilizing Meniscal Tears and Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, James MacKay², Timothy McAlindon¹, Matthew Harkey³, Bing Lu⁴, Charles Eaton⁵, Grace Lo⁶, Mary Barbe⁷ and Robert Ward¹, ¹Tufts Medical Center, Boston, MA, ²University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital; Norwich Medical School, University of East Anglia, Cambridge, United Kingdom, ³University of Massachusetts, Worcester, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁵Brown University, Pawtucket, RI, ⁶Michael E. Debakey VA Medical Center, Baylor College of Medicine, Houston, TX, ⁷Temple University School of Medicine, Philadelphia, PA
Background/Purpose: It is unknown whether early changes in the menisci (e.g., intrameniscal signal alterations) have long-term consequences. We conducted a study to assess the prognostic…
Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Désirée van der Heijde¹, Cynthia E Kartman², Li Xie², Scott Beattie², Douglas Schlichting², Patrick Durez³, Yoshiya Tanaka⁴ and Roy Fleischmann⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…
Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Bruce Kirkham¹, Peter Nash², Sandra Navarra³, Erhard Quebe-Fehling⁴, Corine Gaillez⁴, Carlos Sastre⁴ and Philip Mease⁵, ¹Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ²School of Medicine Griffith University, Brisbane, Queensland, Australia, ³University of Santo Tomas, Manila, Philippines, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…
Abstract Number: 1389 • ACR Convergence 2020
Clinical Characteristics and Treatment Outcome of a Cohort of Patients with Joint and Fascial Involvement in the Context of Chronic Graft versus Host Disease
Cristina Hidalgo Calleja¹, Concepción Román Curto², Luis Gómez-Lechón³, Maria Elisa Acosta², Olga Compán⁴, Sonia Pastor², Carlos Montilla Morales², Lucía Pantoja Zarza⁵, María Dolores Sánchez González⁶ and Lucía López Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, Salamanca, Spain, ³Hospital Francesc de Borga de Gandía, Valencia, Spain, ⁴Hospital Universitario de Salamanca, ´Salamanca, Spain, ⁵Complejo Asistencial Hospital General de Segovia, Segovia, Spain, ⁶Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Background/Purpose: Chronic graft-vs-host disease (cGVHD) is a major late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT), typically occurring within three years post-transplant and affecting…
Abstract Number: 1651 • ACR Convergence 2020
Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies
Shazeen Ayub¹, Jaspreet Kaur¹, Michelle Hui², Michelle Hall¹, Michael Doherty³ and Weiya Zhang¹, ¹Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, United Kingdom, ²Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ³Academic Rheumatology, School of Medicine, University of Nottingham, UK, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis worldwide and is becoming more prevalent with the increasing age of the population. As Intra-articular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].